Total submissions: 4
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Gene |
RCV000658048 | SCV000779819 | uncertain significance | not provided | 2018-05-15 | criteria provided, single submitter | clinical testing | The S74N variant in the EVC2 gene has not been reported previously as a pathogenic variant, nor as a benign variant, to our knowledge. The S74N variant is observed in 2/14,968 (0.013%) alleles from individuals of non-Finnish European background in large population cohorts (Lek et al., 2016). The S74N variant is a conservative amino acid substitution, which is not likely to impact secondary protein structure as these residues share similar properties. In-silico analyses, including protein predictors and evolutionary conservation, support that this variant does not alter protein structure/function. We interpret S74N as a variant of uncertain significance. |
| Illumina Laboratory Services, |
RCV001157338 | SCV001318900 | uncertain significance | Ellis-van Creveld syndrome | 2018-01-13 | criteria provided, single submitter | clinical testing | This variant was observed in the ICSL laboratory as part of a predisposition screen in an ostensibly healthy population. It had not been previously curated by ICSL or reported in the Human Gene Mutation Database (HGMD: prior to June 1st, 2018), and was therefore a candidate for classification through an automated scoring system. Utilizing variant allele frequency, disease prevalence and penetrance estimates, and inheritance mode, an automated score was calculated to assess if this variant is too frequent to cause the disease. Based on the score, this variant could not be ruled out of causing disease and therefore its association with disease required further investigation. A literature search was performed for the gene, cDNA change, and amino acid change (if applicable). No publications were found based on this search. This variant was therefore classified as a variant of unknown significance for this disease. |
| Ambry Genetics | RCV004972836 | SCV005585140 | uncertain significance | Inborn genetic diseases | 2024-10-08 | criteria provided, single submitter | clinical testing | The c.221G>A (p.S74N) alteration is located in exon 1 (coding exon 1) of the EVC2 gene. This alteration results from a G to A substitution at nucleotide position 221, causing the serine (S) at amino acid position 74 to be replaced by an asparagine (N). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
| Labcorp Genetics |
RCV005223086 | SCV005862480 | uncertain significance | Ellis-van Creveld syndrome; Curry-Hall syndrome | 2024-11-13 | criteria provided, single submitter | clinical testing | This sequence change replaces serine, which is neutral and polar, with asparagine, which is neutral and polar, at codon 74 of the EVC2 protein (p.Ser74Asn). The frequency data for this variant in the population databases is considered unreliable, as metrics indicate poor data quality at this position in the gnomAD database. This variant has not been reported in the literature in individuals affected with EVC2-related conditions. ClinVar contains an entry for this variant (Variation ID: 546204). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |